Featured Press Releases

Theralogix Introduces Berberine Enhanced Absorption

Theralogix Introduces Berberine Enhanced Absorption

CollPlant Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Corporate Update

CollPlant Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Corporate Update

  • 20 Aug 2025

CollPlant Biotechnologies a regenerative and aesthetics medicine company developing innovative...

Optune Lua® by Novocure Receives CE Mark Approval for Treating Metastatic Non-Small Cell Lung Cancer

Optune Lua® by Novocure Receives CE Mark Approval for Treating Metastatic Non-Small Cell Lung Cancer

Aspera Biomedicines launched its second ADAR1p150 crystallization to the ISS aboard SpaceX CRS-34

Aspera Biomedicines launched its second ADAR1p150 crystallization to the ISS aboard SpaceX CRS-34

Lasix® ONYU® Receives CE Marking, Advancing Toward International Authorization; EMA Approves for Centralized Review Based on Innovation

Lasix® ONYU® Receives CE Marking, Advancing Toward International Authorization; EMA Approves for Centralized Review Based on Innovation

KODAK PHARMACEUTICALS Expands Its Portfolio and Launches an Online Store in the U.S

KODAK PHARMACEUTICALS Expands Its Portfolio and Launches an Online Store in the U.S

Tenpoint Therapeutics Announces the Launch of the YUVEZZI™ Telehealth Prescribing Program

Tenpoint Therapeutics Announces the Launch of the YUVEZZI™ Telehealth Prescribing Program

  • Tenpoint Therapeutics, Ltd.
  • 09 Nov 2026
BE BOLD: BIMZELX® (bimekizumab-bkzx) demonstrates superior joint response rates versus SKYRIZI® (risankizumab-rzaa) at Week 16, with sustained clinical improvements through Week 24

BE BOLD: BIMZELX® (bimekizumab-bkzx) demonstrates superior joint response rates versus SKYRIZI® (risankizumab-rzaa) at Week 16, with sustained clinical improvements through Week 24

  • UCB
  • 09 Nov 2026
Johnson & Johnson announces that ICOTYDE® (icotrokinra), a once-daily targeted oral peptide, delivers significant improvements in psoriatic arthritis disease activity among biologic-naïve patients

Johnson & Johnson announces that ICOTYDE® (icotrokinra), a once-daily targeted oral peptide, delivers significant improvements in psoriatic arthritis disease activity among biologic-naïve patients

  • Johnson & Johnson
  • 08 Nov 2026
Lilly and Hims & Hers expand access to Lilly

Lilly and Hims & Hers expand access to Lilly's FDA-approved medicines

  • Hims & Hers
  • 06 Nov 2026
Roche Receives FDA 510(k) Clearance for New cobas® eplex Respiratory Pathogen Panel 3, Enabling Customized Respiratory Testing to Meet Local Patient Needs

Roche Receives FDA 510(k) Clearance for New cobas® eplex Respiratory Pathogen Panel 3, Enabling Customized Respiratory Testing to Meet Local Patient Needs

  • Roche Diagnostics
  • 02 Nov 2026
Superpower Launches Peptide Services, Connecting Comprehensive Blood Testing With Prescription Peptide Care

Superpower Launches Peptide Services, Connecting Comprehensive Blood Testing With Prescription Peptide Care

  • Superpower
  • 02 Nov 2026

Most Popular
November   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30            

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.